MAP 2018 - Molecular Analysis for Personalised Therapy

Oncology Meeting Resources

14 Sep - 15 Sep 2018, Paris, France

MAP 2018 - Square

The development of new biotechnologies and their application to Precision Medicine in cancer treatment is a fast-moving field. Understanding molecular alterations, their mechanisms of action and how they can apply to therapy is a challenge in medical oncology and clinical practice.

MAP 2018 is a joint initiative of Cancer Research UK, UNICANCER and ESMO and aims to provide oncologists with expert guidance on interpreting genomic alterations to design tailored treatment programmes for their patients.

Resources from MAP 2018 - Molecular Analysis for Personalised Therapy are available to ESMO member according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...for-Personalised-Therapy/Welcome-to-MAP-2018

Date: 14 Sep 2018
Presenter: Fabrice André
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...lysis-for-Personalised-Therapy/Head-and-neck

Date: 14 Sep 2018
Presenter: Kevin Harrington
Resources: Presentation, Webcast
Topics: Pathology/Molecular Biology, Head and Neck Cancers

https://oncologypro.esmo.org/Meeting-Resour...lysis-for-Personalised-Therapy/Kidney-cancer

Date: 14 Sep 2018
Presenter: Samra Turajlic
Resources: Presentation, Webcast
Topics: Renal Cell Cancer, Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...gy-of-metastatic-cancer-Data-from-DRUP-trial

Date: 14 Sep 2018
Presenter: Emile Voest
Resources: Presentation, Webcast
Topic: Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...sequencing-Profiling-extreme-tumor-diversity

While next-generation sequencing (NGS) has been applied to thousands of solid tumors to date, there exists a fundamental undersampling bias inherent in current methodologies.

Date: 14 Sep 2018
Presenter: Kevin Litchfield
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ecular-Analysis-for-Personalised-Therapy/PDX

Date: 14 Sep 2018
Presenter: Samuel Aparicio
Resources: Presentation, Webcast
Topic: Translational Research

https://oncologypro.esmo.org/Meeting-Resour...sis-for-Personalised-Therapy/Single-cell-PDX

Date: 14 Sep 2018
Presenter: Sohrab Shah
Resources: Presentation, Webcast
Topic: Translational Research

https://oncologypro.esmo.org/Meeting-Resour...-A-prospective-cohort-from-the-MATCH-R-study

ALK tyrosine kinase inhibitors (TKIs) have shown to be effective in the treatment of patients with ALK rearranged NSCLC. The clinical benefit is eventually limited by the acquisition of resistance to ALK TKIs by tumor cells.

Date: 14 Sep 2018
Presenter: Gonzalo Recondo
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ngs-in-sequencing-programs-What-is-the-issue

Date: 14 Sep 2018
Presenter: Thierry Frébourg
Resources: Presentation, Webcast
Topic: Translational Research

https://oncologypro.esmo.org/Meeting-Resour...asion-and-cancer-evolution-The-Achilles-heel

Date: 14 Sep 2018
Presenter: Charles Swanton
Resources: Presentation, Webcast